Pure Global AI
NCT06011460Enrolling by invitation

Observation of Clozapine Treatment Safety in Bipolar Disorder.

Medical University of GdanskClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Bipolar Disorder
Drug/Device/Intervention
Clozapine
Study type
Observational
Intervention type
drug
Sponsor & location
Primary sponsor
Medical University of Gdansk
Location
Gdańsk, Poland
Timeline & enrollment
Phase
N/A
Start date
Feb 23, 2023
End date
Jun 30, 2027
Enrollment
30 participants
Primary outcome

Safety measures of clozapine treatment in patients with bipolar disorder.

Summary

The purpose of the registry is to record incidence of adverse events during treatment with
 clozapine in patients suffering from bipolar disorder.

ICD-10 classifications
Bipolar affective disorderBipolar affective disorder, unspecifiedOther bipolar affective disordersBipolar affective disorder, currently in remissionBipolar affective disorder, current episode mixed
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06011460
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06011460 through Pure Global AI's free database. This phase not specified trial is sponsored by Medical University of Gdansk and is currently Enrolling by invitation. The study focuses on Bipolar Disorder. Target enrollment is 30 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.